NZ727338B2 - IMPROVED Aß PROTOFIBRIL BINDING ANTIBODIES - Google Patents
IMPROVED Aß PROTOFIBRIL BINDING ANTIBODIES Download PDFInfo
- Publication number
- NZ727338B2 NZ727338B2 NZ727338A NZ72733815A NZ727338B2 NZ 727338 B2 NZ727338 B2 NZ 727338B2 NZ 727338 A NZ727338 A NZ 727338A NZ 72733815 A NZ72733815 A NZ 72733815A NZ 727338 B2 NZ727338 B2 NZ 727338B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- antibody
- binding fragment
- seq
- amino acid
- antigen binding
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 7
- 208000035475 disorder Diseases 0.000 claims abstract 5
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract 4
- 230000004845 protein aggregation Effects 0.000 claims abstract 4
- 238000011321 prophylaxis Methods 0.000 claims abstract 3
- 238000003745 diagnosis Methods 0.000 claims abstract 2
- 201000010099 disease Diseases 0.000 claims abstract 2
- 238000002560 therapeutic procedure Methods 0.000 claims abstract 2
- 239000012634 fragment Substances 0.000 claims 25
- 239000000427 antigen Substances 0.000 claims 20
- 102000036639 antigens Human genes 0.000 claims 20
- 108091007433 antigens Proteins 0.000 claims 20
- 125000003275 alpha amino acid group Chemical group 0.000 claims 13
- 201000010374 Down Syndrome Diseases 0.000 claims 5
- 208000009829 Lewy Body Disease Diseases 0.000 claims 5
- 201000002832 Lewy body dementia Diseases 0.000 claims 5
- 206010044688 Trisomy 21 Diseases 0.000 claims 5
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 5
- 102000004169 proteins and genes Human genes 0.000 claims 5
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 201000001320 Atherosclerosis Diseases 0.000 claims 3
- 206010012289 Dementia Diseases 0.000 claims 3
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 3
- 208000018737 Parkinson disease Diseases 0.000 claims 3
- 208000034799 Tauopathies Diseases 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- 210000001124 body fluid Anatomy 0.000 claims 3
- 239000010839 body fluid Substances 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 2
- 230000009885 systemic effect Effects 0.000 claims 2
- 230000009529 traumatic brain injury Effects 0.000 claims 2
- 238000011282 treatment Methods 0.000 claims 2
- 206010002023 Amyloidoses Diseases 0.000 claims 1
- 102220519056 Conserved oligomeric Golgi complex subunit 3_A17D_mutation Human genes 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010002022 amyloidosis Diseases 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 201000010901 lateral sclerosis Diseases 0.000 claims 1
- 210000004558 lewy body Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000022256 primary systemic amyloidosis Diseases 0.000 claims 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 abstract 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 abstract 1
- 206010061818 Disease progression Diseases 0.000 abstract 1
- 230000005750 disease progression Effects 0.000 abstract 1
- 238000012544 monitoring process Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
- C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
Abstract
The present invention relates to the amyloid beta peptide (Aß) and more specifically to antibodies binding to Aß protofibrils and their use in therapy and/or prophylactic treatment of Alzheimer's disease and other disorders associated with Aß protein aggregation. Further the invention may relate to diagnosis of such diseases as well as monitoring of disease progression by use of the antibodies of the invention. Further, the invention may relate to veterinary use of the antibodies of the invention.
Claims (19)
1. An antibody or antigen binding fragment thereof having affinity against Aß ibrils, wherein the antibody or antigen binding fragment thereof comprises a variable light chain comprising an amino acid sequence as set out in SEQ ID NO: 12; 5 and a variable heavy chain comprising an amino acid sequence as set out in SEQ ID NO: 16.
2. An antibody or antigen binding fragment thereof having affinity against Aß ibrils, wherein the antibody or antigen binding fragment thereof comprises a 10 variable light chain comprising an amino acid sequence as set out in SEQ ID NO: 9; and a variable heavy chain comprising an amino acid sequence as set out in SEQ ID NO: 15.
3. An antibody or antigen binding fragment thereof having affinity against Aß 15 protofibrils, wherein the antibody or antigen binding fragment thereof comprises a le light chain comprising an amino acid sequence as set out in SEQ ID NO: 10; and a variable heavy chain comprising an amino acid sequence as set out in SEQ ID NO: 15. 20
4. An antibody or antigen binding fragment f having ty against Aß protofibrils, wherein the antibody or antigen binding fragment thereof comprises a variable light chain comprising an amino acid ce as set out in SEQ ID NO: 11; and a variable heavy chain comprising an amino acid ce as set out in SEQ ID NO: 15.
5. An antibody or n binding fragment thereof having affinity against Aß protofibrils, wherein the antibody or antigen g fragment thereof comprises a variable light chain comprising an amino acid sequence as set out in SEQ ID NO: 12; and a variable heavy chain sing an amino acid sequence as set out in SEQ ID 30 NO: 15.
6. An antibody or antigen binding fragment thereof having affinity against Aß protofibrils, n the antibody or n binding fragment thereof comprises a variable light chain comprising an amino acid sequence as set out in SEQ ID NO: 9; and a variable heavy chain comprising an amino acid sequence as set out in SEQ ID NO: 16.
7. An antibody or antigen binding fragment thereof having affinity against Aß 5 protofibrils, wherein the antibody or antigen binding fragment thereof comprises a variable light chain sing an amino acid sequence as set out in SEQ ID NO: 10; and a variable heavy chain comprising an amino acid sequence as set out in SEQ ID NO: 16. 10
8. An antibody or antigen binding fragment f having affinity against Aß protofibrils, wherein the antibody or antigen binding fragment thereof comprises a le light chain comprising an amino acid ce as set out in SEQ ID NO: 11; and a variable heavy chain comprising an amino acid sequence as set out in SEQ ID NO: 16.
9. The antibody or antigen binding fragment according to any one of claims 1 to 8, wherein the antibody or the antigen g fragment comprises an IgG heavy chain constant region. 20
10. An antibody according to any one of claims 1 to 9, for use in therapy.
11. An antibody according to any one of claims 1 to 9, for use in treatment and/or prophylaxis of Alzheimer’s disease and other disorders associated with Aß protein aggregation.
12. An antibody according to claim 11, for use, wherein the other disorders associated with Aß protein ation are selected from tic brain injury (TBI), Lewy body dementia (LBD), Downs syndrome (DS), ophic lateral sclerosis (ALS), Frontotemporal dementia, tauopathies, systemic amyloidoses, atherosclerosis and 30 Parkinson’s disease dementia (PDD).
13. Use of an antibody according to any one of claims 1 to 9, in the manufacture of a medicament useful in the treatment and/or prophylaxis of Alzheimer’s disease and other disorders associated with Aß protein aggregation.
14. The use according to claim 13, wherein the other disorders associated with Aß protein aggregation are selected from Traumatic brain injury (TBI), Lewy body ia (LBD), Downs syndrome (DS), Amyotrophic lateral sclerosis (ALS), 5 Frontotemporal dementia, tauopathies, systemic doses, atherosclerosis and Parkinson’s disease dementia (PDD).
15. A method for measuring amount of Aß protofibrils and/or aggregated Aß protein in a 10 person, comprising contacting the person’s tissue or body fluid in vitro with the antibody or antigen binding fragment according to claims 1 to 9 and measuring the amount of antibody or antigen binding fragment bound to said Aß protofibrils and/or aggregated Aß protein. 15 16. A method for sis of Alzheimer’s disease in persons having or at risk of developing the disease, comprising contacting the person’s tissue or body fluid in vitro with the antibody or antigen binding fragment ing to claims 1 to 9, or a fragment f, and measuring the amount of said dy bound to ated
Aß protein.
17. A method for diagnosis of traumatic brain injury (TBI), Lewy body dementia (LBD), Down me (DS), Amyotrophic lateral sclerosis (ALS), Frontotemporal dementia, tauopathies, systemic amyloidosis, atherosclerosis and Parkinson’s disease dementia (PDD)in persons having or at risk of developing any of said es, comprising 25 contacting the person’s tissue or body fluid in vitro with the antibody or antigen g fragment according to claims 1 to 9, or a fragment thereof, and measuring the amount of said antibody bound to aggregated Aß protein.
18. A pharmaceutical composition comprising the antibody or n binding fragment 30 according to any one of claims 1 to 9, together with pharmaceutically acceptable excipient and/or diluents.
19. An antibody according to any one of claims 1 to 9, for veterinary use. Figurel Contra! vs A170 E 0.8 S , a 0-5 " E —I— Momma-[Comm 0 % D'?’ " +Monomea’_A17D E —|:|— Protn?bri?tontmi 2 9,2 —0— Protafiba'ii__A17‘D 0.0 mmmmmwwmj—MMWMMMWW "mm? 0.001 0.01 0.1 1 10 100 1000 10000 100000 Amyloid B (nM) Cantral; vs A17D/R825 g +Monomer_Controi z 02 +Monomer_A17D/RSZS —I:I— bfii?ontr? —0— Prota?briLAWD/RBZS 9.0 ~T-----------------T ----------"r~~~~~~~~~~~2 . .“——T 0.001 0.01 0.1 1 10 100 1000 10000 100000 Amvloid [3 {mm} SUBSTITUTE SHEET (RULE 26)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462022952P | 2014-07-10 | 2014-07-10 | |
| PCT/EP2015/065633 WO2016005466A2 (en) | 2014-07-10 | 2015-07-08 | IMPROVED Aß PROTOFIBRIL BINDING ANTIBODIES |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NZ727338A NZ727338A (en) | 2024-08-30 |
| NZ727338B2 true NZ727338B2 (en) | 2024-12-03 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017103446A (en) | IMPROVED ANTIBODIES BINDING β-PROFIBRILLA | |
| MX2021012867A (en) | THERAPEUTICS OF FULLY HUMAN POST-TRANSLATIONALLY MODIFIED ANTIBODIES. | |
| JP6424210B2 (en) | Treatment of a subpopulation of Alzheimer's disease with pooled immunoglobulin G | |
| AU2017291414B2 (en) | Anti-N3pGLu amyloid beta peptide antibodies and uses thereof | |
| WO2021021979A3 (en) | Hdac6 inhibitors and uses thereof | |
| JOP20220092A1 (en) | Anti-beta-amyloid antibody for treating alzheimer's disease | |
| EP4317185A3 (en) | Fully-human post-translationally modified antibody therapeutics | |
| MY205774A (en) | Human il-4r binding antibody, antigen binding fragment thereof, and medical use thereof | |
| EP4631944A3 (en) | Rimegepant for cgrp related disorders | |
| BR112021023487A2 (en) | Anti-tdp-43 binding molecules and uses thereof | |
| BR112014006376A2 (en) | protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease | |
| WO2016087944A3 (en) | Method for treating alzheimer's disease | |
| WO2020132658A3 (en) | Tubulysins and protein-tubulysin conjugates | |
| MX2021012608A (en) | Novel molecules for therapy and diagnosis. | |
| PH12023550032A1 (en) | Tubulysins and protein-tubulysin conjugates | |
| MX2025001920A (en) | Treatment of mitochondrial associated diseases and disorders, including symptoms thereof using pridopidine | |
| BR112021017203A2 (en) | Leucine, acetyl leucine and related analogues for the treatment of diseases | |
| BR112018010337A2 (en) | anti-alpha-v integrin antibody for the treatment of fibrosis and / or fibrotic disorders | |
| MX2021011596A (en) | Compounds and compositions as modulators of tlr signaling. | |
| NZ593312A (en) | Remedies for pemphigus containing anti fas ligand antibodies | |
| NZ727338B2 (en) | IMPROVED Aß PROTOFIBRIL BINDING ANTIBODIES | |
| WO2023081194A3 (en) | Methods for treating alzheimer's disease | |
| WO2020123977A3 (en) | Glial fibrillary acidic protein targeting immuno-and aptamer-based-therapy for neuroinjury, neurodegeneration, neuro-disease, and neuro-repair | |
| JOP20200046A1 (en) | Methods for treating diseases associated with TNF? | |
| AlJadani | Risperidone and carbamazepine combination in treatment of Kluver-Bucy syndrome: a case report |